Open Access
Issue
SHS Web of Conferences
Volume 10, 2014
4th International Interdisciplinary Scientific Conference SOCIETY, HEALTH, WELFARE
Article Number 00021
Number of page(s) 8
DOI https://doi.org/10.1051/shsconf/20141000021
Published online 09 September 2014
  1. Ambulatorajai ārstēšanai paredzēto zāïu un medicınisko ierıču iegādes izdevumu kompensācijas kārtıba. (2006). Ministru kabineta noteikumi Nr.899. Rīga. [Order of reimbursement of medicines and medical devices for outpatient treatment. Regulation No. 899 of the Cabinet of Ministers]. (in Latvian). http://www.likumi.lv/doc.php?id=147522&from=off, accessed 05.05.2013.
  2. Bignami, F. (2007). Eurordis survey on orphan drugs availability in Europe. 6th Eurordis Round Table of Companies Workshop. Barcelona, Spain. http://www.eurordis.org/IMG/pdf/2007ODsurvey-eurordis.pdf, accessed 05.05.2013.
  3. Boon, W., Moors, E. (2008). Exploring emerging technologies using metaphors–a study of orphan drugs and pharmacogenomics. Soc Sci Med, 66, 1915–1927. [CrossRef]
  4. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the regions on Rare Diseases: Europe's challenges. (2008). Commission of the European Communities. Brussels. http://ec.europa.eu/health/ph_threats/non_com/docs/rare_com_en.pdf, accessed 05.05.2013.
  5. de Varax, A., Letellier, M., Börtlein, G. (2004). Study on orphan drugs: Phase I: overview of the conditions for marketing orphan drugs in Europe. Alcimed. Paris, France. http://ec.europa.eu/health/files/orphanmp/doc/pricestudy/final_final_report_part_1_wwe_en.pdf, accessed 05.05.2013.
  6. Denis, A., Mergaert, L., Fostier, C., Cleemput, I., Simoens, S. (2010). A comparative study of European rare disease and orphan drug markets. Health Policy, 97, 173–179. [CrossRef]
  7. Denis, A., Mergaert, L., Fostier, C., Cleemput, I., Simoens, S. (2010). Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. J Med Econ, 13(2), 295–301. [CrossRef]
  8. Drummond, M.F., Wilson, D.A., Kanavos, P., Ubel, P., Rovira, J. (2007). Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care, 23(1), 36–42. [CrossRef]
  9. Iskrov, G., Miteva-Katrandzhieva, T., Stefanov, R. (2012). Challenges to orphan drugs access in Eastern Europe: The case of Bulgaria. Health Policy, 108, 10–18. [CrossRef]
  10. Kompensējamo zālu saraksts. (2013). Nacionālais veselıbas dienests. Rīga. [Reimbursement drug list]. (in Latvian). http://www.vmnvd.gov.lv/lv/kompensejamie-medikamenti/kompensejamo-zalu-saraksts, accessed 05.05.2013.
  11. Latvijas Republikas Zālu reìistrs. (2013). Zālu valsts a‘gentūra. Rīga. [Drug Register of the Republic of Latvia]. (in Latvian). http://www.zva.gov.lv/?id=375&sa=375&top=334, accessed 05.05.2013.
  12. Le Cam, Y. (2010). Inventory of access and prices of orphan drugs across Europe: a collaborative work between national alliances on rare diseases & Eurordis. Eurordis. Paris, France. http://img.eurordis.org/newsletter/pdf/mar-2011/ERTC_13122010_YLeCam_Final.pdf, accessed 05.05.2013.
  13. List of rare disease designations. (2013). European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/orphan_searse.jsp&mid=WC0b01ac058001d12b, accessed 05.05.2013.
  14. Michel, M., Toumi, M. (2012). Access to orphan drugs in Europe: current and future issues. Expert Rev Pharmacoecon Outcomes Res, 12(1), 23–29. [CrossRef]
  15. Orofino, J., Soto, J., Casado, M.A., Oyagüez, I. (2010). Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007. Appl Health Econ Health Policy, 8(5), 301–315. [CrossRef]
  16. Pavlović, N., Stanimirov, B., Stojančević, M., Paut-Kusturica, M., Stoimenova, A., Goločorbin-Kon, S., Mikov, M. (2012). An insight on differences in availability and reimbursement of orphan medicines among Serbia, Bulgaria and Sweden. Biotechnol Biotec Eq, 26(5), 3236–3241.
  17. Picavet, E., Dooms, M., Cassiman, D., Simoens, S. (2011). Drugs for rare diseases: influence of orphan designation status on price. Appl Health Econ Health Policy, 9(4), 275–279. [CrossRef]
  18. Register of designated orphan medicinal products.European Commission. http://ec.europa.eu/health/documents/community-register/html/alforphreg.htm, accessed 05.05.2013.
  19. Regulation (EC) No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products. (2000). Official Journal of the EuropeanCommunities, L18:1-5. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF, accessed 05.05.2013.
  20. Schey, C., Milanova, T., Hutchings, A. (2011). Estimating the budget impact of orphan medicines in Europe: 2010 – 2020. Orphanet J Rare Dis, 6(62), 1–10. [CrossRef]
  21. Simoens, S. (2011). Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis, 6(42), 1–8. [CrossRef]
  22. Spokiene, I. (2008). Legal assessment of current situation on orphan patients in Lithuania. Medicina (Kaunas), 44(8), 571–576.

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.